Director, HEOR Strategy, Global Immunology Pipeline

Role Summary

The Director, HEOR Strategy, Immunology Pipeline leads the development and execution of the integrated HEOR evidence strategy for dermatology pipeline and select rheumatology pipeline assets. Aligns evidence plans with cross-functional asset strategies to advance pipeline assets across all development phases (Ph1 – Ph3). Drives clinical outcomes assessment strategy to secure label-enabling endpoints, generates robust real-world evidence to inform asset development and differentiation, and guides economic value assessments to support access and reimbursement globally. Demonstrates strong cross-functional leadership to influence and align HEOR strategies with matrix teams with the goal of developing compelling product value propositions that drive impact. The Director also uses his/her expertise to build evidence roadmaps that shape long-term disease area strategies and strengthen future portfolio impact. This role can be based in any of the following US locations: Lake County, IL; Cambridge, MA; Irvine, CA; or Florham Park, NJ.

Responsibilities

• Lead HEOR Strategy in development of end-to-end holistic evidence strategy for immunology (rheumatology and dermatology) assets from early proof of concept through Ph3 development, aligning evidence plans with asset differentiation, labeling, and global access objectives.
• Drive matrix decision-making through Pipeline Commercialization Model (PCM), aligning with and influencing clinical development, medical, regulatory, market access, and commercial stakeholders to navigate trade-offs and drive timely, evidence-based decisions.
• Lead Clinical Outcomes Assessment (COA) strategy: select, validate, and operationalize PROs/COAs in trials aligned with asset strategy; engage regulators on endpoint acceptability; and pursue label-enabling claims and differentiation.
• Drive real-world evidence (RWE) generation to inform trial design and target populations, unmet treatment needs, disease burden, patient journey, and future asset value across stakeholders.
• Guide economic value assessments (e.g., cost-effectiveness, budget impact, pricing scenarios, health-state utilities) to define product value, support pricing and reimbursement, and shape asset value narratives.
• Provide leadership in development of early integrated value propositions, creation of value frameworks/narratives, and conduct of affiliate touchpoint engagements to shape asset strategy and evidence generation plans to meet global stakeholder needs
• In collaboration with market access, provide HEOR leadership in development of global value dossiers, HTA strategies, access evidence gap closure plans, scenario analyses, and advisory engagements to anticipate and address payer requirements.
• Shape TA disease area strategies via identification and development of compelling evidence and novel endpoints to anticipate future asset value demonstration needs across stakeholders
• Effectively communicates the findings and strategic impact of research findings to internal (Executive Leadership, Area VPs, GMs etc.) and external (e.g., HTAs/Payors, patient (advocacy groups) and KOLs etc.) audiences

Qualifications

• Advanced degree in Health Economics, Public Health, Epidemiology, Health Services Research or related field required (Master’s or higher; PhD or PharmD/MS preferred)
• Minimum 8 years of experience with Master’s or 6 years of experience with PhD or PharmD/MS in progressively senior roles within Health Economics, Outcomes Research and Market Access in the biotech, pharmaceutical, or healthcare industry
• Experience leading evidence generation activities, including development, validation and/or implementation of COA/PRO measures, in support of pipeline asset development within the pharmaceutical industry strongly preferred
• Immunology therapeutic area experience within the pharmaceutical/biotech industry strongly preferred
• Strong executive presence and presentation skills with demonstrated ability to engage with senior leaders in a cross-functional setting.
• Must be able to develop creative and effective solutions to inter- and intra-project priority conflicts, resource constraints and other problems which may impact project or group goals and deliverables across multiple programs
• Deep knowledge of the global regulatory, payer, and HTA landscape, as well as understanding of other development-related functions as they relate to all phases of drug development.
• Proven leadership skills in a cross-functional global team environment. Ability to interact externally and internally to support global business strategy. Additionally, this person must be able to interact successfully with Senior Management globally (Executive staff, Area VPs, GMs etc.) and act as the HEOR project/group champion and spokesperson
• High goal-orientation with the ability to see solutions rather than problems as projects encounter the inevitable ups and downs associated with new drug development
• Must be a self- starter and have a strong desire to see projects achieve commercial success, including skills to perform the dual roles of leading a cross functional team and managing scientific personnel in clinical research